Adenocarcinoma — Trials

Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

9,697 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,751
Recruiting: 1,519
Ph III recruiting: 167
Growth YoY: +8.6%
Industry share: 23%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,318)

clinicaltrialsPublishedShowing 151–167 of 167 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06221748	DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy	recruiting	Phase 2 / Phase 3	90	RemeGen Co., Ltd.INDUSTRY	1	Apr 3, 2024	clinicaltrials
NCT05760378	Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.	recruiting	Phase 3	223	Fudan UniversityOTHER	1	Feb 6, 2024